If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
=== Therapeutic targeting in autoimmune disease === Therapies seek to disrupt the IgG-FcRn interaction to increase the clearance of disease-causing IgG autoantibodies from the body. One such therapy is the infusion of intravenous immunoglobulin (IVIg) to saturate FcRn's IgG recycling capacity and proportionately reduce the levels of disease-causing IgG autoantibody binding to FcRn, thereby increasing disease-causing IgG autoantibody removal. More recent approaches involve the strategy of blocking the binding of IgG to FcRn by delivering antibodies that bind with high affinity to this receptor through their Fc region or variable regions. These engineered Fc fragments or antibodies are being used in clinical trials as treatments for antibody-mediated autoimmune diseases such as primary immune thrombocytopenia and skin blistering diseases (pemphigus), and the Fc-based inhibitor, efgartigimod, based on the 'Abdeg' technology was recently approved (as 'Vyvgart') for the treatment of generalized myasthenia gravis in December 2021.
Hannibal had a history of the Punic Wars produced, and ordered it to be kept in the temple of Juno Lacinia in Crotone so that the Romans could not falsify the history of the war. Plutarch drew from that source. In the summer of 204 BCE the Romans arrived in Calabria and enslaved the Bruttians to punish their rebellion. Vast estates were requisitioned and assigned to members of the Roman aristocracy. During the Second Punic War (218–201 BCE) the Bruttii allied with Hannibal, who sent Hanno, one of his commanders, to Calabria. Hanno twice marched toward Capua (in Campania) with Bruttian soldiers to take them to Hannibal's headquarters there, but he was twice defeated. When his campaign in Italy came to an end, Hannibal took refuge in Calabria, whose steep mountains provided protection against the Roman legions. He set up his headquarters in Kroton and stayed there for four years until he was recalled to Carthage. The Romans fought a battle with him near Kroton, but its details are not recorded. Many Calabrian cities surrendered to the Romans and Calabria was put under a military commander.
== Arrival in Spain == In Madrid, Alexander von Humboldt pursued the idea of a scientific expedition to Spanish America, despite the usual restrictions on foreign travel in Spanish colonies. Through the assistance of Don Mariano Luis de Urquijo, Spain’s First Secretary of State, whom Humboldt had previously met in London, he was introduced to King Charles IV of Spain. The king granted Humboldt and his companion, Aimé Bonpland, official permission to travel throughout Spanish America for scientific purposes. The royal passports granted Humboldt and Bonpland extensive rights, including the use of scientific instruments, freedom of movement, and the authority to conduct research throughout Spanish territories. Colonial officials were instructed to assist them as needed. Such privileges were exceptional, given that Spain had historically allowed very few foreign scientific missions in its colonies, due to longstanding policies of restricting access to outsiders for reasons of state security, economic monopoly, and religious protection. The level of trust and freedom granted to Humboldt was unprecedented for a non-Spaniard. Humboldt recognized that Spain’s primary interest in granting permission was related to his expertise in mineralogy and the potential for discovering new mineral resources, rather than purely scientific advancement.
Sources: en.wikipedia.org
=== Ukraine === A people's deputy of Ukraine (Ukrainian: народний депутат України, narodnyi deputat Ukrayiny) is a member of parliament or legislator elected by a popular vote to the Verkhovna Rada (the unicameral parliament of Ukraine). Often people's deputies of Ukraine are referred to simply as deputies. The main statutes that define the order of elections, rights and duties of the people's deputies of Ukraine are outlined in Articles 76–81 of the Constitution of Ukraine. There are 450 people's deputies of Ukraine who are elected based on the general, equal and direct electoral right for five years. The deputies may be appointed to various parliamentary positions such as the chairperson (speaker) of parliament, a head of a committee or a parliamentary faction, etc. Upon its appointment, to the office, each people's deputy of Ukraine receives a deputy mandate. People's deputies that run for parliament as self-nominated candidates can join factions if they wish.
=== Available forms === Arsenic trioxide (ATO) is available in both intravenous (IV) and oral formulations for clinical use. The IV form is widely approved and used as the standard for treating acute promyelocytic leukemia (APL), requiring daily infusions. Recent advances have led to the development of oral formulations, including liquid and solid (tablet/pill) preparations, designed to provide comparable bioavailability and efficacy to IV ATO. Specific formulations include:
The "Cave of the Statues" (Statuenhöhle) was a magnificent cave, located next to the "Peacock Cave" (Cave 76). It is a "colossal image cave", with no niche in the main cella, but a podium on which a colossal standing statue of the Buddha probably stood. In an atypical design, the back corridor is quite large and wider than the main cella, with a width of 8.70 meters (342 inches), for a height of 5.10 meters (200 inches). Only seven other "Colossal image caves" are known in Kizil, including caves 47, 48, 70, 136, 139, 146. They are characterized by a very tall main cella designed to accommodate a gigantic image of the Buddha, the height of the cella reaching around 5 meters (16 feet) and sometimes as high as 16.5 meters (650 inches) (such as in cave 47), and also a rather tall back room (often around 5–6 meters; around 200 inches high). The numerous statues of the cave were made of clay and straw, fibers or hair for reinforcement, and often dated to the 6th century CE, but now rather dated to 375–400 CE in conjunction with carbon dates. Many of the statues were made from molds, which had Sanskrit names on them, which are probably the names of the crafsmen or the owners. The cave is a "central pillar" cave, but the roof of the main cella, which formed a vault culminating at around 6 meters (20 feet), has entirely collapsed. A few paintings remained on the walls of the main cella: they were sermons of the Buddha organized in several rows, the size of each of these pictures being 1.34 metres (52 inches) wide and 96 cm (38 inches) high.
Sources: en.wikipedia.org
== Adverse effects == In individuals already taking sulphonylureas, use of DPP-4-class medications concurrently increases their risk for low blood sugar events relative to those on sulphonylureas alone. Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity, and skin reactions. In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling. However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive. A 2014 review found that the use of saxagliptin and alogliptin increased individuals' risk of developing heart failure, leading the FDA to add warnings to the labels of these drugs in 2016. A 2018 meta-analysis indicated that the use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared to placebo or no treatment. Additionally, a 2018 observational study suggested an elevated risk of developing inflammatory bowel disease, specifically ulcerative colitis, which peaked after three to four years of use and decreased after more than four years. Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes.
== Potential applications == The primary proposed benefit of creating mirror-image organisms is as a means to mass-produce mirror-image forms of molecules that are produced by normal life. Mirror-image molecules have been studied for several decades and may offer a range of potential applications. There is broad agreement among scientists that it is important to distinguish between mirror-image molecules and whole mirror-image organisms. Some scientists argue that chemical synthesis methods are sufficient for creating mirror-image molecules without posing the potentially catastrophic risks of mirror-image organisms. Potential applications of mirror-image molecules include:
a reactive negative-feedback system, a reactive feed-forward system, and a predictive or circadian system, The reactive negative-feedback system refers to the system that induces renal secretion of potassium in response to a rise in the plasma potassium (potassium ingestion, shift out of cells, or intravenous infusion). The reactive feed-forward system refers to an incompletely understood system that induces renal potassium secretion in response to potassium ingestion prior to any rise in the plasma potassium. This is probably initiated by gut cell potassium receptors that detect ingested potassium and trigger vagal afferent signals to the pituitary gland. The predictive or circadian system increases renal secretion of potassium during mealtime hours (e.g. daytime for humans, nighttime for rodents) independent of the presence, amount, or absence of potassium ingestion. It is mediated by a circadian oscillator in the suprachiasmatic nucleus of the brain (central clock), which causes the kidney (peripheral clock) to secrete potassium in this rhythmic circadian fashion.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.